MDxHealth SA (MDXH) stock forecast & analysis
1 analysis. Latest: .
Market Scanner’s AI analysis of MDxHealth SA (MDXH), updated August 2026: MDxHealth SA's recent analyses covered Q2 2026 earnings, significant short-term price appreciation, and Nasdaq listing concerns.
Summary
MDxHealth SA's recent analyses covered Q2 2026 earnings, significant short-term price appreciation, and Nasdaq listing concerns.
Recent analyses for MDxHealth SA (MDXH) examined the company's Q2 2026 financial results, which showed a loss but beat revenue estimates, alongside record sequential growth. The reports also tracked significant short-term price appreciation, with the stock trading well above its 50-day SMA but below its 200-day SMA. Additionally, the analyses noted Nasdaq notifications regarding deficiencies in minimum market value and minimum bid price.
MDXH news & sentiment
News reports highlighted MDxHealth SA's Q2 2026 results, noting a loss but exceeding revenue estimates, alongside record sequential growth. Social media discussions tracked significant short-term price appreciation, with indicators suggesting strong buying pressure and overbought conditions, while also acknowledging Nasdaq listing concerns.
MDXH technical picture
MDxHealth SA's recent price action showed strong short-term appreciation, trading well above its 50-day SMA but remaining below its 200-day SMA. Momentum indicators like RSI and MFI signaled extremely strong buying pressure and overbought conditions, while the MACD indicated positive momentum.
Fundamentals
MDxHealth SA's recent analyses covered year-over-year quarterly revenue growth and trailing twelve months revenue, alongside current unprofitability with negative profit and operating margins. The company reported net losses for the fiscal year and the most recent quarter, with no specific mention of cash flow or capital intensity.
Factors discussed — upside
- Strong short-term price appreciation over the last 7 and 30 days.
- Price trading significantly above its 50-day SMA, indicating medium-term upward momentum.
- 10-day EMA below current price, confirming short-term bullish momentum.
- RSI and MFI signaling strong buying pressure and overbought conditions.
- Q2 2026 revenue estimates exceeded, with record sequential growth highlighted.
Factors discussed — risks
- Long-term trend remains bearish as price is considerably below its 200-day SMA.
- Company is currently unprofitable with negative TTM Profit and Operating Margins.
- Reported net loss for fiscal year 2025 and persistent quarterly net losses.
- Received Nasdaq notifications regarding deficiencies in minimum market value.
- Received Nasdaq notifications regarding deficiencies in minimum bid price.
- Technical price trends
- Financial performance
- Regulatory compliance
- Market sentiment
Summary updated .
Analyses
Recent MDXH.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for MDxHealth SA?
- Recent analyses highlighted strong short-term price appreciation and upward momentum, with technical indicators suggesting significant buying pressure. The company also exceeded Q2 2026 revenue estimates and reported record sequential growth.
- What are the risks for MDxHealth SA?
- The long-term trend remains bearish as the stock price is below its 200-day moving average, and the company is currently unprofitable with persistent net losses. Furthermore, MDxHealth SA has received Nasdaq notifications regarding deficiencies in minimum market value and minimum bid price.
- Is MDxHealth SA bullish or bearish?
- Recent AI analyses of MDxHealth SA examined factors on both sides. Discussed upside: Recent analyses highlighted strong short-term price appreciation and upward momentum, with technical indicators suggesting significant buying pressure. The company also exceeded Q2 2026 revenue estimates and reported record sequential growth. Discussed risks: The long-term trend remains bearish as the stock price is below its 200-day moving average, and the company is currently unprofitable with persistent net losses. Furthermore, MDxHealth SA has received Nasdaq notifications regarding deficiencies in minimum market value and minimum bid price. These are descriptive observations, not a recommendation.
- What is the latest sentiment on MDxHealth SA?
- News reports highlighted MDxHealth SA's Q2 2026 results, noting a loss but exceeding revenue estimates, alongside record sequential growth. Social media discussions tracked significant short-term price appreciation, with indicators suggesting strong buying pressure and overbought conditions, while also acknowledging Nasdaq listing concerns.
- Bundles used
- gemini-low-v2
Sign in to read every MDXH.US report in the library
Each analysis includes the full reasoning, dissent, and decision rationale from the structured AI pipeline.